CClinicalTrials.gg
Status unknownNCT02920580NEURO-ETTUpdated Feb 5, 2020

The NEUROlogically-impaired Extubation Timing Trial

An interventional study of Extubation and Usual Care in Acute Brain Injury, sponsored by Sunnybrook Health Sciences Centre. Status unknown at 13 sites in Canada. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

This randomized controlled trial will enrol patients with acute severe brain injury who pass a spontaneous breathing trial but have decreased level of consciousness. It will directly compare (1) prompt extubation vs. (2) usual care, with extubation or tracheostomy timed according to physicians' discretion. The primary outcome will be ICU free days (days spent alive and outside an ICU).

Read the detailed description

Thousands of patients suffer severe brain injuries every year, from causes such as trauma, stroke, and infection. Extensive clinical research in weaning from mechanical ventilation has led to recommendations for prompt extubation following a successful trial of spontaneous breathing in general intensive care unit (ICU). However, little evidence exists to guide decisions about when to remove the breathing tube in patients with severe brain injury. It is unclear which of the following strategies would optimize important patient outcomes: prompt extubation vs. waiting and extubating or performing a tracheostomy, timed according to physicians' discretion. Each strategy has associated risks: prompt extubation may lead to higher rates of extubation failure and reintubation, whereas waiting longer may expose patients to complications from prolonged mechanical ventilation and tracheostomy may lead to procedural complications (or unnecessary procedures, if prompt extubation would be successful). This trial in brain-injured patients will test which of the following will lead to better patient outcomes: (1) removing the endotracheal tube promptly once a spontaneous breathing trial is passed; or (2) usual care, with the airway management strategy selected according to the preference of the treating physician.

02

Conditions studied

  • Acute Brain Injury

Browse trials for

Keywords

  • Subarachnoid hemorrhage
  • Spontaneous intracerebral hemorrhage
  • Global cerebral anoxia/cardiac arrest
  • Meningitis/Encephalitis/Cerebral abscess
  • Seizure
  • Traumatic Brain Injury (TBI)
  • Ischemic Stroke
  • Brain tumor
03

In context

Brain Injuries

2,113 studies on the registry are indexed under Brain Injuries; 385 are open to participants now.

This study's enrollment of 27 is below the median of 48 across 1,331 interventional studies indexed under Brain Injuries.

Browse Brain Injuries studies →

Lead sponsor

Sunnybrook Health Sciences Centre is the lead sponsor of 566 studies on the registry; 134 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age > 16 years
  • Acute brain injury (subarachnoid hemorrhage, ischemic stroke, spontaneous intracerebral hemorrhage, seizure, traumatic brain injury, brain tumor, global cerebral anoxia/cardiac arrest, meningitis/encephalitis/cerebral abscess) that occurred within the previous 4 weeks.
  • Receiving invasive mechanical ventilation via endotracheal tube for > 72 hours
  • Glasgow Coma Scale motor score 3 to 6 with improvement or no change from previous day
  • passed spontaneous breathing trial (SBT)

Exclusion criteria

Exclusion Criteria:

  • Previous extubation during this ICU admission
  • Quadriplegic
  • Neuromuscular disease that will result in prolong need for mechanical ventilation, including but not limited to Guillain-Barre syndrome, cervical spinal cord injury, advanced multiple sclerosis
  • Do-Not-Reintubate order in place
  • Previously randomized in this trial
  • Underlying pre-existing condition with expected mortality less than 6-months.
  • Anticipated/scheduled for surgical procedures within 48 hours
  • C-spine not yet cleared for activity as tolerated (cleared for activity as tolerated while wearing hard collar is acceptable)
  • Currently known or suspected to have an difficult airway
  • Absence of an endotracheal tube cuff leak, if checked
  • Absence of spontaneous or induced cough
  • Current enrolment in an RCT that precludes NEURO-ETT co-enrollment
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Active comparator
    Extubation

    Extubation by removal of endotracheal tube.

    Procedure: Extubation

  • Active comparator
    Usual care

    The usual clinical practice is removal of the endotracheal tube (extubation), or insertion of tracheostomy, timed according to physicians' discretion

    Procedure: Usual Care

Interventions

  • ProcedureExtubation

    This is an extubation by removal of endotracheal tube which must be done on the day of randomization or the following day. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.

  • ProcedureUsual Care

    Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow prompt extubation to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.

06

What researchers measure

Primary outcomes

  1. ICU Free Days

    The primary outcome is number of ICU free days to day 60, defined as the number of days spent alive and outside of an ICU until day 60. The primary outcome will be measured to answer the following primary question: Among patients receiving minimal mechanical ventilatory support for severe and persistent brain injury, which of the following airway management strategies increase ICU-free days to day 60: (1) prompt extubation vs. (2) usual care, which may include extubation or tracheostomy timed according to physicians' discretion?

    Time frame: 60 days

Secondary outcomes

  1. Mortality,

    Mortality at ICU discharge, mortality at hospital discharge, mortality at 3 months, mortality at 6 months

    Time frame: up to 6 months

  2. Ventilator-Free Days

    Days free of mechanical ventilation, total duration (days) of ventilation among survivors

    Time frame: up to 60 days

  3. Airway Complications

    Presence versus absence of airway complication

    Time frame: up to 60 days

  4. Nutrition Intake

    Time to normal oral nutrition intake

    Time frame: up to 6 months

  5. Antibiotic Days

    Injection or infusion of antibiotics given intravenously

    Time frame: up to day 14

  6. Delirium

    Presence versus absence of delirium experienced

    Time frame: up to day 14

  7. Rate of Tracheostomy Insertion

    Presence versus absence of tracheostomy insertion

    Time frame: up to 6 months

  8. Rate of ICU Readmission

    ICU readmission rates to hospital discharge

    Time frame: up to hospital discharge

  9. Hospital Discharge Destination

    Destination of the patient post hospitalization - home, rehabilitation facility, retirement home, long-term care/nursing home, no fixed address or shelter, continuing complex care, acute care hospital, other

    Time frame: at hospital discharge

  10. Extended Glasgow Outcome Score

    Functional outcome (scoring 1 to 8)

    Time frame: up to 6 months

  11. EQ-5D

    Health related quality of life (scoring 1 to 5)

    Time frame: up to 6 months

07

Study locations

13 sites
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Royal Columbian Hospital
    New Westminster, British Columbia V3L 3W7, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Hamilton General Hospital
    Hamilton, Ontario L8N 3Z5, Canada
  • Kingston General Hospital
    Kingston, Ontario K7L 2V7, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Toronto Western Hospital
    Toronto, Ontario M5G 2N2, Canada
  • Centre hospitalier de l'Université de Montréal
    Montreal, Quebec H2X 2H8, Canada
  • Hôpital du Sacré-Cœur de Montréal
    Montreal, Quebec H4J 1C5, Canada
  • L'Hôpital de l'Enfant-Jésus
    Quebec City, Quebec G1J 1Z4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02920580
Lead sponsor
Sunnybrook Health Sciences Centre
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Dr. Damon Scales (MD, PhD, FRCPC, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
Sep 30, 2016
Start date
Feb 1, 2017
Primary completion
Jun 19, 2019
Completion
Jan 31, 2022 (estimated)
Last update
Feb 5, 2020

Study contacts

Niall Ferguson, MD, MSc,
principal investigator · Toronto General Hospital
Damon Scales, MD, PhD
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion